A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG

Allergologia et Immunopathologia

Volumn 42, Issue 2, 2014, Pages 136-141

  Lozano Blasco, J ^a   Martin Mateos M A ^a   Alsina, L ^a   Dominguez O ^a   Giner, M T ^a   Piquer, M ^a   Alvaro, M ^a   Plaza, A M ^a  

^a HOSPITAL SANT JOAN DE DÉU   (Spain)

Author keywords

Adverse events; Efficacy; Intravenous immunoglobulin; Paediatrics; Primary immunodeficiency

Indexed keywords

ANTIBIOTIC AGENT; DEXCHLORPHENIRAMINE; IMMUNOGLOBULIN G; PARACETAMOL; IMMUNOGLOBULIN;

ABDOMINAL PAIN; ADOLESCENT; AGAMMAGLOBULINEMIA; ANAPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BODY WEIGHT; CHILD; CHILDHOOD DISEASE; CHILL; CLINICAL ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; CONTINUOUS INFUSION; COUGHING; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG SYNTHESIS; DRUG TOLERANCE; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HYPER IGM SYNDROME; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; INFUSION RATE; INFUSION RELATED REACTION; MALE; MEDICAL RECORD REVIEW; OPEN STUDY; PRESCHOOL CHILD; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; REST; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SWEATING; VOMITING; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGY;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MALE;

EID: 84897027403     PISSN: 03010546     EISSN: 15781267     Source Type: Journal    
DOI: 10.1016/j.aller.2012.10.006     Document Type: Article

References (30)

1. Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res 2007, 38:122-132.
2. Stiehm E.R., Vaerman J.P., Fudenberg H.H. Plasma infusions in immunologic deficiency states: metabolic and therapeutic studies. Blood 1996, 28:918-937.
3. Ammann A.J., Ashman R.F., Buckley R.H., Hardie W.R., Krantmann H.J., Nelson J., et al. Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial. Clin Immunol Immunopathol 1982, 22:60-67.
4. Buckley R.H., Schiff R.I. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991, 325:110-117.
5. Cunningham-Rundles C., Siegal F.P., Smithwick E.M., Lion-Boulé A., Cunningham-Rundles S., O'Malley J., et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med 1984, 101:435-439.
6. Orange J.S., Hossny E.M., Weiler C.R., Ballow M., Berger M., Bonilla F.A., et al. Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006, 117:525-552.
7. Shah S.R. A newer immunoglobulin intravenous (IGIV) - Gammard liquid 10%: evaluation of efficacy, safety, tolerability and impact on patient care. Expert Opin Biol Ther 2008, 8:799-804.
8. ®, at different infusion rates. J Clin Immunol 2010, 30:442-448.
9. ® 20% for subcutaneous use. Immunotherapy 2011, 3:163-176.
10. Stein M.R., Nelson R.P., Church J.A., Wasserman R.L., Borte M., Vermylen C., et al. IgPro10 in PID study group: safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol 2009, 29:137-144.
11. Sinclair C.J., Brooks W., Genereux M.G. Comparative pharmacokinetics of liquid and lyophlized formulations of IV RhUG immune globulin. Biologicals 2008, 36:256-262.
12. Pautard B., Hachulla E., Bagot d'Arc M., Chantreuil L. Intravenous immunoglobulin (endobulin) clinical tolerance: prospective therapeutic follow-up of 142 adults and children. Rev Med Interne 2003, 24:505-513.
13. Bolli R., Spycher M.O., Brügger R., Wüst B., Gennari K. IgG-dimer formation in liquid immunoglobulin preparations is inhibited by nicotinamide and other amphiphilic compounds. J Autoimmun 1999, 96:96.
14. Schnorf J., Arnet B., Burek-Kozlowska A., Gennari K., Rohner R., Spath P.J., et al. Laboratory parameters measured during infusion of immunoglobulin preparations for intravenous use and related to tolerability. Intravenous immunoglobulin research and therapy 1996, 312-313. Parthenon, New York. M.D. Kazatchkine, A. Morell (Eds.).
15. Spycher M.O., Bolli R., Hodler G., Gennari K., Hubsch A., Späth P. Well-tolerated liquid intravenous immunoglobulin G preparations (IVIG) have a low immunoglobulin G dimer (IgGdimer) content. J Autoimmun 1999, (Suppl. 1):96.
16. Privigen® CSL Behring. EMEA; 2008.
17. Hagan J.B., Wasserman R.L., Baggish J.S., Spycher M.O., Berger M., Shashi V., et al. Safety of l-proline as a stabilizer for immunoglobulin products. Expert Rev Clin Immunol 2012, 8:169-178.
18. Kumar T.K., Samuel D., Jayaraman G., Srimathi T., Yu C. The role of proline in the prevention of aggregation during proten folding in vitro. Biochem Mol Biol Int 1998, 46:509-517.
19. Kiovig® Baxter Healthcare Corporation. EMEA; 2006.
20. Endobulin® Baxter Healthcare Corporation. Agencia Española de Medicamentos y productos Sanitarios; 2002.
21. Chapel H. Classification of primary immunodeficiency diseases by the International Union of Immunological Societies (IUIS) Expert Committee on Primary Immunodeficiency 2011. Clin Exp Immunol 2012, 168:58-59.
22. Treatment experiences and preferences of patient with primary immune deficiency diseases. Survey results presented at the immune deficiency foundation meeting, 20 June 2003.
23. Darbà J., Restovic G., Kaskens L., de Agustín T. Direct medical costs of liquid intravenous immunoglobulins in children, adolescents, and adults in Spain. J Clin Pharmacol 2011, 52:566-575.
24. Wasserman R.L., Church J.A., Stein M., Moy J., White M., Strausbaugh S., et al. Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency. J Clin Immunol 2012, 32:663-669.
25. Flebogamma® 5% Prescribing Information 2003, Grifols S.A.
26. ® liquid summary basis of approval 2004, Baxter Healthcare Corporation.
27. Brennan V.M., Salome-Bentley N.J., Chapel H.M. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 2003, 133:247-251.
28. Eijkhout H.W., van Der Meer J.W., Kallenberg C.G., Weening R.S., van Dissel J.T., Sanders L.A., et al. Inter-University Working Party for the Study of Immune Deficiencies: the effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 2001, 135:165-174.
29. Roifman C.M., Levison H., Gelfand E.W. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1987, 1:1075-1077.
30. Stiehm E.R. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr Infect Dis J 1997, 16:696-707.